Relmada Therapeutics (RLMD) Change in Accured Expenses (2014 - 2026)

Relmada Therapeutics (RLMD) has reported Change in Accured Expenses for 13 consecutive years, with -$1.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 28.94% year-over-year to -$1.6 million; the TTM figure through Mar 2026 stood at -$664189.0 (up 79.29% YoY), while the FY2025 annual figure was -$1.3 million, up 48.61% from the prior year.
• Change in Accured Expenses slipped to -$1.6 million in Q1 2026 per RLMD's latest filing, from $1.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $6.6 million in Q2 2022 and bottomed at -$3.1 million in Q4 2022.
• Historically, Change in Accured Expenses has averaged -$33305.9 across 5 years, with a median of -$193775.0 in 2025.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 664.92% — and 2024, when it sank 1143.14%.
• Relmada Therapeutics' Change in Accured Expenses stood at -$3.1 million in 2022, then jumped by 199.33% to $3.1 million in 2023, then sank by 86.57% to $419607.0 in 2024, then jumped by 168.13% to $1.1 million in 2025, then plunged by 238.6% to -$1.6 million in 2026.
• Business Quant data shows RLMD's Change in Accured Expenses at -$1.6 million in Q1 2026, $1.1 million in Q4 2025, and -$36140.0 in Q3 2025.